Bartlett & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bartlett & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$14.4M	Sell	280,510 -99,303	-26%	-$5.21M	0.23%	80
2023 Q3	$22M	Sell	379,813 -210,231	-36%	-$12.9M	0.4%	60
2023 Q2	$37.7M	Sell	590,044 -270,369	-31%	-$18.1M	0.65%	48
2023 Q1	$59.6M	Buy	860,413 +7,082	+0.8%	+$500K	1.15%	28
2022 Q4	$61.4M	Buy	853,331 +3,004	+0.4%	+$227K	1.24%	26
2022 Q3	$60.5M	Buy	850,327 +5,839	+0.7%	+$424K	1.3%	27
2022 Q2	$65.5M	Sell	844,488 -11,190	-1%	-$852K	1.33%	23
2022 Q1	$62.9M	Buy	855,678 +24,291	+3%	+$1.63M	1.1%	29
2021 Q4	$51.8M	Sell	831,387 -49,373	-6%	-$2.9M	0.88%	40
2021 Q3	$52.1M	Buy	880,760 +13,716	+2%	+$903K	0.99%	35
2021 Q2	$57.9M	Buy	867,044 +2,713	+0.3%	+$177K	1.11%	32
2021 Q1	$54.6M	Buy	864,331 +37,236	+5%	+$2.32M	1.1%	31
2020 Q4	$51.3M	Buy	827,095 +1,772	+0.2%	+$109K	1.1%	29
2020 Q3	$49.8M	Buy	825,323 +39,679	+5%	+$2.39M	1.17%	25
2020 Q2	$46.2M	Buy	785,644 +59,007	+8%	+$3.53M	1.21%	22
2020 Q1	$40.5M	Buy	+726,637	New	+$44.4M	1.23%	23
2019 Q3	$33.8M	Buy	666,446 +168,185	+34%	+$7.9M	0.89%	36
2019 Q2	$22.6M	Buy	498,261 +138	+0%	+$6.43K	0.84%	47
2019 Q1	$23.8M	Buy	498,123 +58,482	+13%	+$2.91M	0.91%	43
2018 Q4	$22.9M	Sell	439,641 -47,862	-10%	-$2.57M	0.97%	39
2018 Q3	$30.3M	Buy	487,503 +798	+0.2%	+$47.4K	1.14%	33
2018 Q2	$26.9M	Sell	486,705 -43,319	-8%	-$2.34M	1.1%	35
2018 Q1	$33.5M	Buy	530,024 +4,027	+0.8%	+$259K	1.38%	24
2017 Q4	$32.2M	Sell	525,997 -17,747	-3%	-$1.11M	1.28%	28
2017 Q3	$34.7M	Buy	543,744 +12,681	+2%	+$740K	1.45%	23
2017 Q2	$29.6M	Buy	531,063 +2,759	+0.5%	+$150K	1.33%	23
2017 Q1	$28.7M	Buy	528,304 +20,259	+4%	+$1.11M	1.31%	25
2016 Q4	$29.7M	Buy	508,045 +6,828	+1%	+$373K	1.4%	23
2016 Q3	$27M	Buy	501,217 +57,235	+13%	+$3.68M	1.3%	29
2016 Q2	$32.7M	Buy	443,982 +34,803	+9%	+$2.46M	1.61%	18
2016 Q1	$26.1M	Buy	409,179 +371,584	+988%	+$23.4M	1.31%	29
2015 Q4	$2.59M	Sell	37,595 -120	-0.3%	-$7.93K	0.13%	103
2015 Q3	$2.23M	Sell	37,715 -2,075	-5%	-$132K	0.12%	100
2015 Q2	$2.65M	Sell	39,790 -3,019	-7%	-$199K	0.13%	96
2015 Q1	$2.76M	Sell	42,809 -133	-0.3%	-$8.33K	0.14%	95
2014 Q4	$2.54M	Buy	42,942 +400	+0.9%	+$22.6K	0.12%	101
2014 Q3	$2.18M	Sell	42,542 -5,627	-12%	-$281K	0.11%	103
2014 Q2	$2.34M	Buy	48,169 +560	+1%	+$27.6K	0.11%	99
2014 Q1	$2.47M	Hold	47,609	–	–	0.12%	94
2013 Q4	$2.53M	Sell	47,609 -500	-1%	-$25.5K	0.13%	94
2013 Q3	$2.23M	Sell	48,109 -1,449	-3%	-$63.6K	0.12%	96
2013 Q2	$2.21M	Buy	+49,558	New	+$2.15M	0.12%	96

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bartlett & Co's BMY Position: Q4 2023 in Review

Bartlett & Co reduced its Bristol-Myers Squibb (BMY) stake by 26% in Q4 2023, selling an estimated $5.21M and leaving 280,510 shares worth $14.4M. The position accounts for 0.23% of the portfolio, ranked #80.

Bartlett & Co first reported a position in BMY in Q2 2013 and has held it in 42 quarters since. The position peaked at $65.5M in Q2 2022. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Bartlett & Co held 280,510 shares of Bristol-Myers Squibb worth $14.4M as of Q4 2023.
Bartlett & Co sold 99,303 Bristol-Myers Squibb shares in Q4 2023, an estimated $5.21M.
Bristol-Myers Squibb made up 0.23% of Bartlett & Co's portfolio in Q4 2023, its #80 holding.
Bartlett & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 42 quarters since.
Bartlett & Co's Bristol-Myers Squibb position peaked at $65.5M in Q2 2022.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.